AbbVie Inc. (ABBV): Capital Expenditures
$1.21B
Year ended 2025-12-31
$1.30B
Trailing 12 months to 2026-06-30
+20.4%
3-year compound annual growth
+8.8%
5-year compound annual growth
+8.6%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.21B | +24.6% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $974.00M | +25.4% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $777.00M | +11.8% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $695.00M | -11.7% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $787.00M | -1.4% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $798.00M | +44.6% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $552.00M | -13.5% | 2022-02-18, From 2019-01-01 |
| 2018-12-31 | $638.00M | +20.6% | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $529.00M | +10.4% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $479.00M | -10.0% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $532.00M | -13.1% | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | $612.00M | +24.6% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $491.00M | +47.4% | 2016-02-19, From 2013-01-01 |
| 2012-12-31 | $333.00M | -6.5% | 2015-02-20, From 2012-01-01 |
| 2011-12-31 | $356.00M | n/a | 2014-02-21, From 2011-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| AbbVie Inc. (ABBV) | 2025-12-31 | $1.21B | +24.6% |
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.84B | +55.0% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $501.00M | +0.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $898.40M | +18.9% |
Compare ABBV, PFE, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗